Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient
概览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Comparison of diagnostic performances (specificity and sensitivity) between ultra-low dose and low dose CT scanner
概览
简要总结
Hereditary hemorrhagic telangiectasia (HHT) is linked to a dysregulation of angiogenesis leading to the formation of arteriovenous malformations (AVM): cutaneo-mucous telangiectasia and visceral shunts. The diagnosis is clinical and based on Curaçao criteria: recurrent epistaxis, cutaneo-mucous telangiectasia, hereditary signs and presence of visceral AVM.
Pulmonary AVMs (PAVM) expose patients to many potentially life-threatening complications, such as strokes or brain abscesses due to the right-left shunt created and the lack of filtration barrier of the pulmonary capillary within the AVM. These patients should therefore have regular monitoring throughout their life by a chest CT scanner every 5 to 10 years in the absence of PAVM at the initial scan or more often if PAVMs are present. The management of PAVMs is based on their early detection and embolization in interventional radiology during which is set up within the afferent artery of the PAVM an embolizing agent, the coil.
However, the risk of cumulative irradiation exposure from thoracic scanners and repeated thoracic embolizations over time could be reduces by a decrease of X-rays dose.
A new thoracic CT imaging protocol validated in the United States in the primary screening of lung cancer, the ultra-low dose protocol, is a CT scanner acquired at an irradiation dose equivalent to that of a frontal chest x-ray and in profile. The dose reduction is of 40 times the usual dose of a chest CT scanner.
The lung parenchyma has a high natural contrast on thoracic CT images and there are few adjacent attenuating structures allowing a drastic reduction of dose. However, from this dose, the image quality is degraded with an increase of the image noise. The diagnostic performances have to be confirmed with qualitative and quantitative measurements.
Thus, the objective of this study is to compare the sensitivity and the specificity of the current scanner and the ultra-low dose scanner to reduce the exposure to X-rays.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient monitored for a clinically confirmed Rendu-Osler disease and / or confirmed by molecular biology, seen for an initial assessment or for a reassessment of PAVM (after treatment or without treatment)
- •Patient who agreed to participate in the study and signed the written informed consent
- •Patient affiliated to a social security scheme or similar
排除标准
- •Women who are pregnant, nursing (lactating) or at risk of pregnancy (verified by a urine test before performing the scanner)
- •Patient who is protected adults under the terms of the law (French Public Health Code).
- •Patient who has not or poorly understand French
结局指标
主要结局
Comparison of diagnostic performances (specificity and sensitivity) between ultra-low dose and low dose CT scanner
时间窗: Day one
calculation of the sensibility, specificity and the predictive values using the Pearson's method after judgment of the presence or absence of pulmonary AVM to treat on each acquisition (low dose and ultra-low dose).
次要结局
- the effective radiation dose(at thoracic CT acquisition - day one)
- the dose length product (DLP)(at thoracic CT acquisition - day one)
- the size of efferent vein(At the two re-readings - 3 months)
- the size of afferent artery(At the two re-readings - 3 months)
- the number of afferent artery(At the two re-readings - 3 months)
- the computed tomography dose index (CTDI)(at thoracic CT acquisition - day one)
- the quality of images(At the two re-readings - 3 months)
- the confidence of the diagnosis(At the two re-readings - 3 months)